Vaccitech Q3 net income $8.2M; cash $200.1M; first patient dosed in VTP-300 Phase 2b

Barinthus Biotherapeutics plc.

2022-Q3 EPS reported $0.69 revenue$38,246,000

Net income of $8.2M ($0.22 per share) vs $15.7M in Q2 2022; revenue fell to $6.2M from $17.1M as no milestones.
Cash and equivalents $200.1M as of Sep 30, 2022, down from $214.1M at Dec 31, 2021; cash runway into Q1 2025.
Dosed first patient in Phase 2b trial of VTP-300 for HBV; Phase 1b/2a data showed HBsAg reduction in CHB patients.
Promoted Gemma Brown to CFO effective Sep 20, 2022.
Expects to open Phase 1/2 trial for prostate cancer candidate VTP-850 in Q4 2022; IND submissions for SNAPvax programs in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Barinthus Biotherapeutics plc. reported third quarter ended September 30, 2022 results: revenue $6.2 million, net income $8.2 million, EPS $0.22 both per fully diluted share and per basic share.

Period: third quarter ended September 30, 2022
Revenue: $6.2 million
Net income: $8.2 million
EPS: $0.22 both per fully diluted share and per basic share
Result: reported results

Exact text from the filing

Revenues comprised primarily of the Company’s share of milestone and royalty payments received by OUI from AstraZeneca related to commercial sales of Vaxzevria ® . Revenues were $6.2 million in the third quarter of 2022 compared to $17.1 million in the second quarter of 2022, with the reduction attributable to no milestones being achieved in the third quarter of

View on SEC.gov

Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.